Komal Jhaveri, MD, clinical director for early drug development service at Memorial Sloan Kettering Cancer Center, and Julie Nangia, MD, medical director of breast oncology at Baylor College of Medicine, discuss a randomized phase 3 study of datopotamab deruxtecan vs chemotherapy — how does this trial change our treatment algorithm?

Terry Mamounas, MD, medical director of the Comprehensive Breast Program at Orlando Health Cancer Institute, speaks with Hope Rugo, MD, about radiation management of the axilla after response to neoadjuvant therapy – can we de-escalate?

Carol Fabian, MD, director of breast cancer prevention and survivorship at the University of Kansas Medical Center, and Seema Khan, MD, professor of breast surgical oncology at Northwestern Medicine, discuss breast cancer prevention.

Sara Hurvitz, MD, FACP, Senior Vice President and director of the Clinical Research Division at Fred Hutchinson Cancer Center, speaks to SABCS Program Director Kate Lathrop, MD, about the primary analysis of HER2CLIMB-02: Tucatinib and Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer.

Jason Mouabbi, MD, assistant professor and medical oncologist at MD Anderson Cancer Center, speaks with SABCS Program Director Kate Lathrop, MD, about the challenges of treating lobular breast cancer and impactful scientific advancements to be presented at SABCS.